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ABSTRACT
Background: Fluoxetine is an inhibitor of the main metabolizing enzymes 
(cytochrome P450 [CYP] 2C19 and CYP3A4) of omeprazole and thus might influ-
ence that drug’s pharmacokinetics. The changes in omeprazole’s pharmacokinetics 
may have clinical significance concerning efficacy and tolerability of the treatment.
Objective: The aim of this study was to assess the pharmacokinetic interaction 
of fluoxetine with omeprazole in healthy volunteers.
Methods: The study enrolled healthy adult men and consisted of 2 periods. In 
the first period, all subjects received a single 40-mg dose of omeprazole. This was followed 
by an 8-day period during which fluoxetine monotherapy (60 mg/d) was administered 
as a single oral daily dose. At the end of those 8 days, the subjects were administered 
a 40-mg dose of omeprazole with a 60-mg dose of fluoxetine. Plasma concentrations 
of omeprazole were determined at 0.5, 1, 1.33, 1.66, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 
and 12 hour(s) after study drug administration. Omeprazole plasma concentrations 
were determined by a validated HPLC method. Pharmacokinetic parameters of omep-
razole were calculated using noncompartmental analysis. Adverse events were assessed 
throughout the study duration.
Results: Eighteen healthy male volunteers (mean [SD] age, 22.11 [2.52] years 
[range, 18–26 years]; body mass index, 23.34 [2.31] kg/m2 [range, 19.1–27.1 kg/m2]) 
were enrolled and completed the study. In the 2 periods of treatment, the mean Cmax 
of omeprazole was 730.8 ng/mL (omeprazole monotherapy) and 1725.5 ng/mL 
(combination treatment with fluoxetine). The observed AUC0–t was 1453.3 and 
5072.5 ng/mL/h and AUC0–∞ was 1465.0 and 5185.3 ng/mL/h, respectively. The Tmax 
was 1.30 and 1.63 hours and the elimination rate constant was 0.753 and 0.482 hr–1. 
The t1/2 was 0.96 and 1.47 hours, whereas the mean residence time was 2.33 and 
3.35 hours, respectively. Statistically significant differences were observed for all pa-
rameters between periods 1 and 2 (all, P < 0.001).
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Conclusion: The data found in this prospective pilot study suggest a pharma-
cokinetic interaction between fluoxetine and omeprazole in these healthy volunteers, 
but its relevance has to be confirmed. (Curr Ther Res Clin Exp. 2010;71:360–368) 
© 2010 Elsevier HS Journals, Inc.
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INTRODUCTION
Omeprazole, 5-methoxy-2-[{(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl} sulfoxide]-
1H-benzimidazole, is a gastric parietal cell proton-pump inhibitor. The drug has greater 
antisecretory activity than histamine hydrogen–receptor antagonists and has been used 
in the treatment of peptic ulcer, efflux esophagitis, and Zollinger–Ellison syndrome.1,2 
The bioavailability of omeprazole is 20% to 30% after the first dose, and it increases to 
~60% with repeated doses. One potential reason for these characteristics is that the 
metabolism of omeprazole can be saturated over time, which is indicative of nonlinear 
pharmacokinetics.3,4 Omeprazole is metabolized in the liver to the primary metabolites 
5-hydroxyomeprazole and omeprazole sulfone. The formation of 5-hydroxyomeprazole 
is mainly mediated by the isoenzyme cytochrome P450 (CYP) 2C19, whereas the forma-
tion of omeprazole sulfone is via CYP3A4.5–7 Omeprazole is generally well tolerated.2 
The most common adverse reactions reported (with an incidence rate ≥2%) included 
headache (6.9%), abdominal pain (5.2%), nausea (4.0%), diarrhea (3.7%), vomiting 
(3.2%), and flatulence (2.7%). Nervousness, abnormal heartbeat, muscle pain, weak-
ness, leg cramps, and water retention have also been reported.
Fluoxetine is an antidepressant for oral administration that is efficacious through selec-
tive inhibition of serotonin reuptake.8 Fluoxetine is metabolized by N-demethylation 
to its active metabolite, norfluoxetine.8 The elimination t1/2 of fluoxetine has been re-
ported to be between 1 and 4 days, while that of norfluoxetine is longer, ranging from 
7 to 15 days.8 The mean elimination t1/2 of fluoxetine increases (from 1.9–5.7 days) with 
multiple doses, due to inhibition of its own metabolism.8 Fluoxetine and its metabolite 
have been shown to be inhibitors of CYP2D6, CYP2C19, and CYP3A4.9,10
Being an inhibitor of the primary metabolizing enzymes of omeprazole, fluoxetine 
might influence its pharmacokinetics and it is important to determine whether a 
pharmacokinetic interaction occurs between these drugs. To date, this pharmacoki-
netic interaction has not been reported.
SUBJECTS AND METHODS
Subjects
Healthy, nonsmoking males, aged ≥18 years, were enrolled in the study. We uti-
lized our subject recruitment database. Potential subjects submitted a prestudy inter-
view and complete medical history; physical examination was conducted by a clinical 
investigator. The study was conducted according to the principles of the Declaration 
of Helsinki (1964) and its amendments (Tokyo 1975, Venice 1983, Hong Kong 
1989). The clinical protocol was reviewed and approved by the Ethics Committee of 
the University of Medicine and Pharmacy “Iuliu Hatieganu,” Cluj-Napoca, Romania. 
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As provided in the study protocol, written informed consent was obtained from each 
subject prior to enrollment. All subjects were informed of their rights and obligations, 
potential adverse effects, and other study details. The volunteers were to be healthy 
according to medical history, physical examination, and laboratory tests, have no his-
tory of alcohol or drug abuse, and not be taking any medication. For the conclusion 
of the study, each subject underwent a final medical examination. All subjects were 
financially compensated for their participation in the study.
Study Design
The study consisted of 2 periods: period 1 (reference), when each volunteer received 
a single 40-mg dose of omeprazole* (2 enteric-coated capsules containing omeprazole 
20 mg); and period 2 (test), when each volunteer received a single 40-mg dose of omep-
razole and a 60-mg dose of fluoxetine† (three 20-mg capsules). Between the 2 periods, 
the subjects were treated for 8 days with a single daily 60-mg dose of fluoxetine. It 
was assumed that this dose of fluoxetine would result in plasma concentrations similar 
to those obtained after 6 weeks’ administration of a 20-mg daily dose.11 All study 
drugs were administered in the morning, following an overnight fast. A standardized 
meal was provided 3 hours after drug administration.
During each study period, venous blood (5 mL) was drawn into heparinized tubes 
before study drug administration (time 0) as well as at 0.5, 1, 1.33, 1.66, 2, 2.5, 3, 4, 
5, 6, 7, 8, 10, and 12 hour(s) after drug administration; the separated plasma was 
stored at –20°C until analysis.
Although the therapeutically recommended daily dose of fluoxetine is 20 mg, a 
previous study found that treatment with 60 mg/d for ~1 week results in plasma 
concentrations similar to those obtained after 6 weeks’ administration of a 20-mg 
daily dose.11 It was for this reason that the 60-mg dose of fluoxetine was chosen.
Analysis of Plasma Samples
Omeprazole plasma concentrations were determined by a validated HPLC method 
with ultraviolet (UV) detection. The HPLC system (binary pump, autosampler, thermo-
stat, UV detector; Agilent 1100 series, Agilent Technologies, Darmstadt, Germany) 
was used together with a C18 column (75 mm × 4.6 mm; inner diameter, 3.5 μm; 
Zorbax SB-C18, Agilent Technologies). The mobile phase consisted of 33:67 (V/V) 
acetonitrile:monopotassium phosphate solution 30 mM (pH, 6.5) in water. The flow 
rate was 1.5 mL/min and the thermostat temperature was set at 35°C. UV detection 
was made at 303 nm. In a centrifuge tube, 100 μL disodium hydrogen phosphate 
0.1 M and 6 mL 1/1 diethyl ether/dichloromethane (v/v) were added to 0.5 mL of 
plasma. The tube was capped and shaken for 5 minutes on a vortex mixer. After cen-
trifugation (2000g) and separation, the organic layer was evaporated under a stream of 
nitrogen at 35°C. The residue was dissolved in 200 μL of mobile phase and a 50-μL 
sample was injected into the chromatographic system. The calibration curve was lin-
*Trademark: Omeran™ (Europharm SA, Brasov, Romania).
†  Trademark: Fluoxin™ (Vim Spectrum SRL, Corunca, Romania).
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ear over a concentration range of 8 to 4000 ng/mL plasma, with a correlation coeffi-
cient r > 0.995. At the lower limit of quantification (8 ng/mL), accuracy and precision 
were 8.8% and 7.2% (intraday) and 11.7% and 10.2% (interday), respectively.
Pharmacokinetic Analysis
Noncompartmental pharmacokinetic analysis was performed to determine the 
pharmacokinetic parameters of omeprazole monotherapy or in combination with flu-
oxetine. The Cmax and Tmax were obtained directly by the visual inspection of each 
subject’s plasma concentration–time profile. The AUC0–t was calculated using the 
trapezoidal rule. AUC0–∞ was determined by the following formula:
AUC0–∞ = Ct/kel + AUC0–t,
where Ct was the last quantifiable drug concentration and kel was the elimination rate 
constant. The kel was estimated by the least squares regression of plasma concentration–
time data points lying in the terminal log-linear region of the curves. The t1/2 was 
calculated as 0.693/kel. The mean residence time (MRT) was calculated as follows:
MRT = AUMC0–∞⁄AUC0–∞,
where the area under the first moment curve (AUMC0–∞) was calculated from the 
plasma concentration–time curve as the product of time and the plasma drug concen-
tration versus time from time 0 to ∞. All pharmacokinetic analyses were performed 
using Kinetica version 4.2 (Thermo Labsystems, Waltham, Massachusetts).
Tolerability Analysis
Tolerability assessment included adverse events (AEs) and vital signs, which were 
recorded throughout the study. Chemistry and hematology analysis were also recorded 
on inclusion and after completing the study.
Statistical Analysis
ANOVA was used to compare the calculated pharmacokinetic parameters of omepra-
zole (log-transformed) for the 2 periods, using general linear model procedures, in which 
sources of variation were subject and treatment. In order to evaluate a possible clinical 
significance of the pharmacokinetic interaction, the bioequivalence assessment method-
ology was applied.12–15 The 90% CIs of the log-transformed test/reference period ratios 
for Cmax, AUC0–t, and AUC0–∞ (each log transformed) were determined by the Schuir-
mann two 1-sided t test.16 The bioequivalence between omeprazole in the test and refer-
ence periods could be concluded if the 90% CIs for these pharmacokinetic parameters 
of the 2 periods were found to be within an accepted range of 0.8 to 1.25.12–14 Regard-
ing the analysis of Tmax, the limit for bioequivalence range was expressed as untrans-
formed data, the significance of the difference of Tmax (test/reference) being established 
by a nonparametric test (Friedman test). All statistical analyses were performed using 
Kinetica version 4.2 software (Thermo Labsystems).
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RESULTS
Eighteen healthy male volunteers (mean [SD] age, 22.11 [2.52] years [range, 18– 
26 years]; body mass index, 23.34 [2.31] kg/m2 [range, 19.1–27.1 kg/m2]) were enrolled 
and completed the study.
The mean plasma concentrations of omeprazole monotherapy or in combination 
with fluoxetine, after 8 days treatment with fluoxetine, are shown in the figure.
The mean pharmacokinetic parameters of omeprazole monotherapy or in combina-
tion with fluoxetine, as well as the statistical significance following their comparison 
are shown in Table I.
The mean (SD) Cmax of omeprazole, before and after the fluoxetine multiple-dose 
administration (730.8 [430.0] vs 1725.5 [493.1] ng/mL; P < 0.001), was sig- 
nificantly different between the 2 periods, as was also found to be the case when compar-
Combination treatment
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Figure.  Mean (SD) plasma levels of omeprazole (40 mg PO) administered alone (dotted 
line) or in combination with oral fluoxetine 60 mg after treatment with fluoxetine 
60 mg PO for 8 days (continuous line) in healthy male volunteers (N = 18).
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ing AUC0–t (1453.3 [1151.5] vs 5072.5 [1715.5] ng/mL/h; P < 0.001), AUC0–∞ 
(1465.0 [1158.5] vs 5185.3 [1795.0] ng/mL/h; P < 0.001), kel (0.753 [0.217] vs 
0.482 [0.171] h–1; P < 0.001), MRT (2.33 [0.57] vs 3.35 [0.41] h; P < 0.001), and 
t1/2 (0.96 [0.30] vs 1.47 [0.25] h; P < 0.001). However, Tmax was not significantly 
different between periods (1.30 [0.54] vs 1.63 [0.39] h).
The parametric 90% CIs for the log-transformed test/reference ratio of the mean 
pharmacokinetic parameters Cmax, AUC0–t, and AUC0–∞ of omeprazole and the signifi-
cance of the difference of Tmax (test/reference, mean values) are shown in Table II.
Omeprazole and fluoxetine administered alone or in combination were well tolerated 
by all subjects participating in the study. Mild gastrointestinal (nausea, xerostomia, 
heartburn, diarrhea, anorexia) and central nervous system (fatigue, sedation, insomnia, 
dizziness) AEs were reported during the repeated administration of fluoxetine and 
after administration of fluoxetine and omeprazole in combination. Two subjects re-
Table I.  Pharmacokinetic parameters of omeprazole (40 mg PO) administered alone or 
after treatment with fluoxetine 60 mg PO for 8 days in healthy male volunteers 
(N = 18). Data are mean (SD).
 Omeprazole Omeprazole + 
Parameter Monotherapy Fluoxetine P*
Cmax, ng/mL  730.8 (430.0) 1725.5 (493.1) <0.001
Tmax, h 1.30 (0.54) 1.63 (0.39) –
AUC0–t, ng/mL/h 1453.3 (1151.5) 5072.5 (1715.5) <0.001
AUC0–∞, ng/mL/h  1465.0 (1158.5) 5185.3 (1795.0) <0.001
kel, h
–1 0.753 (0.217) 0.482 (0.171) <0.001
t1/2, h 0.96 (0.30) 1.47 (0.25) <0.001
MRT, h 2.33 (0.57) 3.35 (0.41) <0.001
kel = elimination rate constant; MRT =  mean residence time.
*ANOVA.
Table II.  Bioequivalence evaluation of pharmacokinetic parameters 
of omeprazole (40 mg PO) administered alone or after treat-
ment with fluoxetine 60 mg PO for 8 days in healthy male 
volunteers (N = 18).
Pharmacokinetic 
Parameter 90% CIs P
AUC0–∞ 2.06–3.41 0.001*
AUC0–t 1.99–3.38 0.001*
Cmax 1.30–1.70 0.001*
Tmax
† – 0.761‡
*ANOVA.
†  D2 = 3.841.
‡ Friedman test.
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ported mild heartburn and dizziness, respectively, when omeprazole alone was admin-
istered. No clinically relevant changes were observed in laboratory parameters, blood 
pressure, or heart rate before and after omeprazole and fluoxetine treatment.
DISCUSSION
The 90% CIs for the geometric mean of omeprazole in individual test/reference ratios 
for Cmax, AUC0–t, and AUC0–∞ were outside the acceptable limits to assume bioequiv-
alence (0.8–1.25). The lack of bioequivalence between omeprazole administered alone 
or in combination with fluoxetine raises the possibility that the pharmacokinetic in-
teraction between these drugs may be of clinical significance.
The difference between mean Tmax values of omeprazole in the test and reference 
periods was not statistically significant, indicating that the rate of absorption is not 
significantly changed. Omeprazole metabolism in humans is mediated through the 
CYP2C19 and CYP3A4 enzymes5–7 and fluoxetine has an inhibitory effect on them.9,10 
Therefore, the observed pharmacokinetic interaction might be due to a reduced meta-
bolic clearance of omeprazole which may affect both the presystemic and systemic elimi-
nation of the drug. Any reduction in the presystemic metabolism is likely to result in a 
reduced first-pass effect, increased bioavailability, and, consequently, increased Cmax and 
AUC0–∞. At the same time, a decrease in systemic metabolism will also contribute to an 
increase of Cmax, AUC0–∞, and the t1/2 of omeprazole.
Omeprazole is an integral part of the eradication drug regimens used for all 
Helicobacter pylori–positive individuals with gastric and duodenal ulcers. These regi-
mens combine omeprazole with antimicrobials such as amoxicillin, clarithromycin, 
and metronidazole. It was suggested that the higher plasma concentration of omepra-
zole might be associated with higher effectiveness in anti-H pylori treatment,17–19 and 
possibly with higher stability of antimicrobials in the higher intragastric pH.20 This 
might result in a higher rate of ulcer eradication. Further study is necessary to deter-
mine whether or not concomitant administration of fluoxetine is clinically relevant 
as adjunctive treatment for eradication of H pylori because of AEs associated with 
fluoxetine.
Although no AEs were associated with the increased omeprazole exposure during 
the fluoxetine administration in this study, repeated administration of both omepra-
zole and fluoxetine might lead to omeprazole-related AEs. Polymyositis and other 
myopathies occurring in patients treated with omeprazole have been identified as pos-
sible adverse drug reactions. Reported muscle problems might be a result of an inter-
action leading to increased plasma concentrations of omeprazole.21
Omeprazole, as with other proton-pump inhibitors, is associated with dose-dependent 
increases in serum gastrin concentrations that may lead to enterochromaffin-like hyper-
plasia as a result of the hypergastrinemia22; however, there has been no evidence that 
these changes result in dysplasia, carcinoid tumors, or gastric adenocarcinoma. Long-
term omeprazole treatment in H pylori–positive patients is associated with progressive 
atrophic gastritis of the gastric body. The risk of AEs might be higher in elderly pa-
tients because of factors such as age-related physiological changes, diseases, genetic 
constitution, and diet that may alter drug response.23 
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The present study has several limitations that should be noted. The use of a 60-mg dose 
of fluoxetine for 8 days may approximate long-term plasma levels (as in the case of long-
term 20-mg administration) but it may not reflect the same rate of metabolism (priming 
of cytochrome systems). Some patients require long-term maintenance treatment with 
both fluoxetine and omeprazole. Because a single-dose administration of omeprazole does 
not fully simulate clinical practice, further studies are required by using multiple dos-
ing design (steady state) for both omeprazole and fluoxetine. Also, the interaction 
with fluoxetine, which also inhibits CYP2C19, was not studied. This was a small study 
in healthy volunteers; further clinical trials are required to confirm the results.
CONCLUSION
The present study found that the pretreatment of healthy volunteers with a single 
daily dose of fluoxetine 60 mg for 8 days prior to the administration of omeprazole 40 mg 
significantly changed the pharmacokinetics of omeprazole; however, the relevance of 
this finding needs to be confirmed.
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